首页> 外文OA文献 >Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN

【2h】

Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN

机译：Myelofibrosis是Jak2 Triilinear Myelloveriferative肿瘤（MPN）和Calr和MPL血小板血症中的次要事件：用于新建的前触发MPN的新型治疗方案的含义

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Michiels JJ; Berneman Z; Gadisseur A; Raeve HD; Schroyens W; Potter V; Schelfout K; Valster F;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. CALR, JAK2, and MPL Mutation Profiles in Patients With Four Different Subtypes of Myeloproliferative Neoplasms Primary Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera, and Myeloproliferative Neoplasm, Unclassifiable [J] . Kim Seon Young, Im Kyongok, Park Si Nae, American journal of clinical pathology. . 2015,第5期

机译：具有四个不同亚型的骨髓增生性肿瘤患者的CALR，JAK2和MPL突变谱原发性骨髓纤维化，原发性血小板增多症，真性红细胞增多症和骨髓增生性肿瘤，无法分类
2. Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN) [J] . Isfort Susanne, Stegelmann Frank, Klausmann Martine, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：诸如血栓栓塞事件的合并症显着恶化患者报告的寿生质质量（QOL）和肌酚类肿瘤（MPN）的症状 - 来自德国研究组的MPN（GSG-MPN）的生物学
3. UK UK results from the myeloproliferative neoplasms ( MPN MPN ) landmark survey on the symptom, emotional and economic burden of MPN MPN [J] . Harrison Claire, Mathias Jonathan, Campbell‐Drew Maz, British Journal of Haematology . 2019,第3期

机译：英国英国的肌源肿瘤（MPN MPN）标志性调查结果来自MPN MPN的症状，情感和经济负担
4. Transcriptional and Proteomic Changes Associated with the Sensitivity and Resistance to JAK2 Inhibitors: Implications for the Treatment of BCR-ABL (-) Myeloproliferative Neoplasms (MPNs). [D] . McDevitt, Theresa Marie. 2012

机译：与JAK2抑制剂的敏感性和抗性相关的转录和蛋白质组学变化：对BCR-ABL（-）骨髓增生性肿瘤（MPNs）的治疗意义。
5. 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2 MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications [O] . Jan Jacques Michiels, Mihaela Tevet, Adrian Trifa, 2016

机译：在2016年新的WHO分类中由JAK2MPL和CALR基因中的MPN驱动基因突变引起的骨髓增生性肿瘤（MPN）的分类和分期的2016 WHO临床分子和病理学标准：预后和治疗意义
6. Prospective evaluation of WHO and European clinical, molecular and pathological (WHO-ECMP) criteria for myeloproliferative neoplasms (MPN) of various molecular etilogiy: characterisitcs of JAK2 V617F, MPL 515 and CALR mutated MPN [O] . Michiels JJ, Devos Timothy, Fostier K, 2015

机译：世卫组织和欧洲针对各种分子病的骨髓增生性肿瘤（MPN）的临床，分子和病理学（WHO-ECMP）标准的前瞻性评估：JAK2 V617F，MPL 515和CALR突变的MPN的特征

Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN

著录项

相似文献

相关主题

期刊订阅